CoChat

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic Properties of the GPR40 Agonist TAK‐875: Results From a Double‐Blind, Placebo‐Controlled Single Oral Dose Rising Study in Healthy Volunteers

Naik, Himanshu, Vakilynejad, Majid, Wu, Jingtao, Viswanathan, Prabhakar, Dote, Nobuhito, Higuchi, Tomoaki, Leifke, Eckhard · 2012 · The Journal of Clinical Pharmacology
Cited by 88

The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.

Abstract

TAK‐875 is a selective G‐protein‐coupled receptor 40 agonist in development for the treatment of type 2 diabetes mellitus. This randomized, double‐blind, placebo‐controlled study evaluated the safety, tolerability, pharmacokinetics, and pharmacodynamics of TAK‐875 following administration of a single oral dose of TAK‐875 (25–800 mg) in 60 healthy volunteers. TAK‐875 was eliminated slowly with a mean terminal elimination t 1/2 of approximately 28.1 to 36.6 hours. Systemic exposure of TAK‐875 did not exhibit dose‐proportional increases across the dose range evaluated due to a greater than proportional increase in exposure at doses greater than 200 mg. A preliminary food effect assessment indicated that coadministration of TAK‐875 with a high‐fat meal decreased C max of TAK‐875 by 40% and AUC by 17%. Clinical adverse experiences were generally mild and transient. No dose‐dependent pattern was observed. In healthy volunteers, no glucose‐lowering effect and no increase in insulin or c‐peptide secretion were evident following administration of TAK‐875; the frequency of plasma glucose concentrations <70 mg/dL was similar in the TAK‐875 and pooled placebo groups. TAK‐875 was well tolerated in the study and has pharmacokinetic characteristics suitable for a once‐daily regimen. The pharmacodynamic data support the notion that TAK‐875, if effective in diabetic patients, may bear a low risk of hypoglycemia.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1177/0091270011409230

Cites

7 of 7 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 7 references

Cited by

See all 88

Metadata

Authors
Naik, H., Vakilynejad, M., Wu, J., Viswanathan, P., Dote, N., Higuchi, T., & Leifke, E.
Venue
The Journal of Clinical Pharmacology
Publisher
Wiley
Published
2012-07
Volume
52
Issue
7
Pages
1007-1016
ISSN
  • 0021-9754 (ISSN-L)
  • 0091-2700
  • 1552-4604
OpenAlex
W2147024197
Cited by
88
References
7
FWCI
8.24
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic Properties of the GPR40 Agonist TAK‐875: Results From a Double‐Blind, Placebo‐Controlled Single Oral Dose Rising Study in Healthy Volunteers. https://app.cochat.ai/papers/10.1177/0091270011409230
The paper
Naik, H., Vakilynejad, M., Wu, J., Viswanathan, P., Dote, N., Higuchi, T., & Leifke, E. (2012). Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic Properties of the GPR40 Agonist TAK‐875: Results From a Double‐Blind, Placebo‐Controlled Single Oral Dose Rising Study in Healthy Volunteers. The Journal of Clinical Pharmacology. https://doi.org/10.1177/0091270011409230

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.